New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models [PDF]
Viruses, 2021 Antiretroviral therapy (ART) controls human immunodeficiency virus 1 (HIV-1) replication and prevents disease progression but does not eradicate HIV-1.
Katherine M. Bricker +2 more
doaj +4 more sources
Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy [PDF]
Cell Reports, 2019 Summary: Latent proviruses persist in central (TCM), transitional (TTM), and effector (TEM) memory cells. We measured the levels of cellular factors involved in HIV gene expression in these subsets.
Marion Pardons +4 more
doaj +4 more sources
Latency Reversing Agents and the Road to an HIV Cure [PDF]
PathogensHIV-1 infection cannot be cured due to the presence of HIV-1 latently infected cells. These cells do not produce the virus, but they can resume virus production at any time in the absence of antiretroviral therapy. Therefore, people living with HIV (PLWH)
Louis Tioka +3 more
doaj +4 more sources
Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy? [PDF]
Viruses, 2021 AIDS first emerged decades ago; however, its cure, i.e., eliminating all virus sources, is still unachievable. A critical burden of AIDS therapy is the evasive nature of HIV-1 in face of host immune responses, the so-called “latency.” Recently, a ...
Thanarat Salahong +2 more
doaj +4 more sources
HIV Latency Reversing Agents have diverse effects on Natural Killer Cell Function [PDF]
Frontiers in Immunology, 2016 In an effort to clear persistent HIV infection, and achieve a durable therapy-free remission of HIV disease, extensive pre-clinical studies and early pilot clinical trials are underway to develop and test agents that can reverse latent HIV infection and ...
Carolina Garrido +11 more
doaj +4 more sources
Impact of latency‐reversing agents on human macrophage physiology [PDF]
Immunity, Inflammation and Disease, 2023 Introduction HIV‐1 eradication is hindered by the presence of inducible long‐lived reservoirs of latently infected cells which rapidly disseminate viral particles upon treatment interruption.
Laurent Hany +4 more
doaj +2 more sources
Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs [PDF]
Frontiers in Microbiology, 2020 One of the most explored therapeutic approaches aimed at eradicating HIV-1 reservoirs is the “shock and kill” strategy which is based on HIV-1 reactivation in latently-infected cells (“shock” phase) while maintaining antiretroviral therapy (ART) in order
Amina Ait-Ammar +9 more
doaj +2 more sources
HIV latency reversing agents act through Tat post translational modifications [PDF]
Retrovirology, 2018 Background Different classes of latency reversing agents (LRAs) are being evaluated to measure their effects in reactivating HIV replication from latently infected cells.
Georges Khoury +9 more
doaj +2 more sources
Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells [PDF]
Pathogens and ImmunityBackground: Latency reversing agents (LRAs) such as protein kinase C (PKC) modulators can reduce rebound-competent HIV reservoirs in small animal models.
Melanie Dimapasoc +8 more
doaj +2 more sources
Ethnopharmacological exploration and isolation of HIV-1 latency-reversing agents from Sudanese medicinal plants [PDF]
Frontiers in PharmacologyHIV-1 infection remains a major health challenge, especially in resource-limited settings such as Sudan, where traditional medicine is widely practiced for managing infectious diseases, including HIV/AIDS.
Khaled M. Elamin +13 more
doaj +2 more sources